Belluscura PLC (LSE:BELL) has terminated a $1.5 million Loan Note arrangement with Omaha Value, Inc following a failure to receive the agreed funds, leading to the cancellation of associated warrants. The company is currently reviewing strategic alternatives to maximize stakeholder value, including the possibility of selling key assets and intellectual property to a U.S.-based medical device firm.
This potential transaction is under a 15-day exclusivity period for due diligence. Meanwhile, Belluscura’s shares remain suspended as the company continues discussions on funding and delays the completion of its 2024 Annual Report.
About Belluscura PLC
Belluscura PLC is a UK medical device company focused on developing oxygen enrichment technologies for various industrial and therapeutic uses.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply